Meet Samuel – Your Personal Investing Prophet

• Start a conversation with TipRanks’ trusted, data-backed investment intelligence
• Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds

The latest announcement is out from CanSino Biologics, Inc. Class H ( (HK:6185) ).

CanSino Biologics Inc. has initiated a Phase I/II clinical trial for its 24-valent pneumococcal polysaccharide conjugate vaccine, PCV24, and completed enrollment of the first patient. The vaccine uses dual carrier and covalent conjugation technology and is intended for individuals from six weeks of age and older to prevent diseases caused by 24 pneumococcal serotypes.

PCV24 builds on the company’s previously approved 13-valent pneumococcal vaccine iPneucia®, further expanding its pneumococcal portfolio in a field where no 24-valent conjugate vaccine is yet available globally. The trial will assess safety and immunogenicity, and a successful outcome could strengthen CanSino’s competitive position in the pneumococcal vaccine market and broaden its revenue prospects over the long term.

The most recent analyst rating on (HK:6185) stock is a Buy with a HK$64.00 price target. To see the full list of analyst forecasts on CanSino Biologics, Inc. Class H stock, see the HK:6185 Stock Forecast page.

More about CanSino Biologics, Inc. Class H

CanSino Biologics Inc. is a China-based biopharmaceutical company specializing in the research, development and commercialization of innovative vaccines. Its portfolio includes pneumococcal conjugate vaccines such as the 13-valent iPneucia®, and it targets broad immunization needs across age groups in both domestic and potentially global markets.

Average Trading Volume: 980,117

Technical Sentiment Signal: Sell

Current Market Cap: HK$11.95B

For an in-depth examination of 6185 stock, go to TipRanks’ Overview page.